LLY
Eli Lilly and Company
Healthcare · Drug Manufacturers - General · United States · Stock
Score Breakdown
Scored for Dividend Income profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- LLY received maximum sub-scores of 20.0 in both growth and profitability — reflecting the FY2025 10-K documenting exceptional year-over-year revenue growth and strong net and operating margins — which together contribute 40 of the 78.1 composite points.
- The dividend sub-score of 18.8 out of 20 is among the strongest in the model framework, driven by FCF payout coverage, a sustained DPS streak, and a competitive DPS growth CAGR as derived from SEC filing data, aligning LLY strongly with the dividend income goal profile.
- The momentum sub-score of 15.0 confirms that financial improvement has been directionally consistent across multiple quarters within the fiscal year, providing additional confidence that the annual filing's strong numbers reflect a durable operating trend rather than a one-time event.
Why Not Higher
- The financial health sub-score of 14.0 out of 20 reflects leverage and interest coverage metrics in the 10-K that are solid but below the levels required to score in the 17-20 range, acting as a structural drag on the composite score given the capital-intensive growth investment underway.
- The theme sub-score of 0.0 out of 20 contributes zero points to the composite, meaning the model did not identify macro thematic exposure signals from the filing, leaving up to 20 points of potential composite score unrealized and explaining why the total does not approach the 95+ range despite dual-maximum growth and profitability scores.
Data Confidence
9 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Eli Lilly and Company is a global pharmaceutical manufacturer headquartered in Indianapolis, Indiana, with a diversified portfolio spanning diabetes care, oncology, immunology, and neuroscience. The company has become particularly prominent through its GLP-1 receptor agonist franchise, including tirzepatide-based therapies marketed under the Mounjaro and Zepbound brands, which have driven exceptional recent revenue expansion. Based on FY2025 10-K data filed with SEC EDGAR, the model assigned LLY a composite score of 78.1/100, reflecting near-perfect growth and profitability sub-scores of 20.0 each — a rare double-maximum outcome indicating both explosive top-line expansion and strong margin generation simultaneously. The momentum sub-score of 15.0 further confirms that quarterly financial improvements have been sustained across revenue, earnings, and margins, not merely a one-period event. The dividend sub-score of 18.8 out of 20 is particularly notable and explains why the best-fit profile for this filing is dividend income at 84.4. This score reflects strong free cash flow payout coverage, a consistent dividend per share streak, meaningful DPS growth CAGR, and an FCF-backed dividend structure — suggesting Lilly's dividend program is well-supported by the underlying cash generation of the business according to the filings. The financial health sub-score of 14.0 out of 20, while solid, introduces some moderation: leverage ratios and interest coverage figures derived from the 10-K indicate the balance sheet carries a meaningful debt load, which is common in large-cap pharma but acts as a ceiling on this sub-score. The key research tradeoff for LLY is between its exceptional operating performance and dividend profile on one hand, and its financial health and zero theme score on the other. The theme sub-score of 0.0 means the model found no macro thematic exposure tags in the filing data, which tempers the composite score and explains why the safe long-term investing profile scores lowest at 77.3. Researchers evaluating LLY through this model should weigh outstanding fundamental metrics against the leverage position and the absence of thematic signals when forming a research view.
Plain English
Eli Lilly makes blockbuster medicines — including the widely discussed diabetes and weight-loss drugs Mounjaro and Zepbound — and it scored 78.1 out of 100 on this model, earning a 'Strong Candidate' label with a Medium risk rating. The high score is driven by exceptional revenue growth and profit margins showing up in its annual SEC filing, plus a dividend that looks well-covered by free cash flow. The Medium risk rating reflects the fact that while the business is performing very strongly, the company carries notable debt on its balance sheet, which can amplify outcomes in both directions. For researchers focused on dividend income, this filing profile scores even higher at 84.4, making LLY one of the stronger research candidates in that goal category based on the available data.
Bull Case vs. Bear Case
Bull Case
- Both the growth and profitability sub-scores reached the maximum of 20.0 out of 20, indicating the FY2025 10-K shows simultaneously exceptional year-over-year revenue and net income expansion alongside strong net margins, operating margins, and return on assets — a combination rarely achieved at this company's scale.
- The dividend sub-score of 18.8 out of 20 reflects a filing-supported picture of a well-covered, consistently growing dividend, with free cash flow payout ratios and DPS growth CAGR both contributing positively, suggesting the income stream is structurally sound based on the regulatory filings.
- The momentum sub-score of 15.0 out of 20 indicates that the strong financial results seen in the annual filing are supported by sequential quarterly improvement in revenues, earnings, and margins — reducing the probability that the headline annual growth figure was a single-quarter anomaly.
Bear Case
- The financial health sub-score of 14.0 out of 20 signals that the balance sheet carries elevated leverage as reflected in the 10-K's debt metrics and interest coverage ratios, meaning a slowdown in revenue growth could disproportionately pressure financial flexibility and debt servicing capacity.
- The theme sub-score of 0.0 out of 20 indicates the model identified no macro thematic exposure from the filing data, which may reflect how the 10-K characterizes the business and limits the composite score ceiling, resulting in the weakest profile score of 77.3 for safe long-term investing.
- Large-cap pharmaceutical manufacturers like Lilly face structural risks including patent cliffs on key products, potential generic or biosimilar competition, and drug pricing legislative pressure — all of which are disclosed as risk factors in 10-K filings and could impair the exceptional growth trajectory currently reflected in the model's top sub-scores.
What Could Change the Picture
Bullish Triggers
- A subsequent 10-K filing showing meaningful reduction in the leverage ratio and improvement in interest coverage — reflecting debt paydown from strong free cash flow generation — would likely lift the financial health sub-score from 14.0 toward the 17-20 range, adding materially to the composite score.
- If future filings begin to capture macro thematic exposure tags — for example, through expanded digital health, AI-assisted drug discovery, or obesity treatment ecosystem disclosures — the theme sub-score could move from 0.0 toward 20.0, potentially pushing the composite model score well above 90.
Bearish Triggers
- A future 10-K showing a deceleration in revenue or net income growth — for example, due to competitive GLP-1 entrants, formulary exclusions, or pricing pressure from policy changes — would directly compress the growth sub-score from its current maximum of 20.0, reducing the composite score significantly.
- Evidence in a future filing of deteriorating free cash flow relative to dividend payments — which would reduce FCF payout coverage and potentially break the DPS growth streak — would weaken the dividend sub-score from 18.8, undermining the primary reason LLY scores so strongly against the dividend income goal profile.
Red Flags
- The financial health sub-score of 14.0, while not alarming in isolation, combined with the scale of capital investment required to expand GLP-1 manufacturing capacity as referenced in 10-K capital expenditure disclosures, suggests leverage levels warrant ongoing monitoring in future filings.
Risk Profile
Medium RiskThe Medium risk rating for LLY reflects a balance between the company's demonstrated operational strength — as evidenced by maximum growth and profitability scores — and its meaningful leverage position captured in the financial health sub-score of 14.0, which indicates the balance sheet is not in a pristine low-debt condition. In large-cap pharmaceutical manufacturing, the combination of heavy capital expenditures for capacity expansion and the binary risk of pipeline or patent outcomes creates a risk profile that is elevated relative to more defensive sectors even when current fundamentals are exceptional.
Key Catalysts to Watch
The primary catalyst to monitor from a filing-data perspective is the trajectory of revenue and free cash flow in subsequent 10-K and quarterly disclosures, particularly whether the growth driving the current dual-maximum sub-scores is sustained as GLP-1 market dynamics evolve and manufacturing investments mature. Secondary attention should be paid to balance sheet developments — specifically whether debt levels stabilize or decline relative to earnings — as this would be the most direct pathway to improving the financial health sub-score and lifting the overall composite model score.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.